The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
Open accessAbstract
BACKGROUND: A substantial number of patients with rheumatoid arthritis have an inadequate or unsustained response to tumor necrosis factor alpha (TNF-alpha) inhibitors. We conducted a randomized, double-blind, phase 3 trial to evaluate the efficacy and safety of abatacept, a selective costimulation modulator, in patients with active rheumatoid arthritis and an inadequate response to at least three months of anti-TNF-alpha therapy. METHODS: Patients with active rheumatoid arthritis and an inadequate response to anti-TNF-alpha therapy were randomly assigned in a 2:1 ratio to receive abatacept or placebo on days 1, 15, and 29 and every 28 days thereafter for 6 months, in addition to at least one disease-modifying antirheumatic drug. Patients discontinued anti-TNF-alpha therapy before randomization. The rates of American College of Rheumatology (ACR) 20 responses (indicating a clinical improvement of 20 percent or greater) and improvement in functional disability, as reflected by scores for the Health Assessment Questionnaire (HAQ) disability index, were assessed. RESULTS: After six months, the rates of ACR 20 responses were 50.4 percent in the abatacept group and 19.5 percent in the placebo group (P<0.001); the respective rates of ACR 50 and ACR 70 responses were also significantly higher in the abatacept group than in the placebo group (20.3 percent vs. 3.8 percent, P<0.001; and 10.2 percent vs. 1.5 percent, P=0.003). At six months, significantly more patients in the abatacept group than in the placebo group had a clinically meaningful improvement in physical function, as reflected by an improvement from baseline of at least 0.3 in the HAQ disability index (47.3 percent vs. 23.3 percent, P<0.001). The incidence of adverse events and peri-infusional adverse events was 79.5 percent and 5.0 percent, respectively, in the abatacept group and 71.4 percent and 3.0 percent, respectively, in the placebo group. The incidence of serious infections was 2.3 percent in each group. CONCLUSIONS: Abatacept produced significant clinical and functional benefits in patients who had had an inadequate response to anti-TNF-alpha therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Choy, E. H. S., & Panayi, G. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441207 · Cited by 2,249
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
Self-citationWeinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Self-citation
Cited by
Cytokines in the pathogenesis of rheumatoid arthritis
McInnes, I. B., & Schett, G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2094 · Cited by 2,529
Diagnosis and Management of Rheumatoid Arthritis: A Review
Aletaha, D., & Smolen, J. S. (2018) · JAMA · doi:10.1001/jama.2018.13103 · Cited by 2,313
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
Fife, B. T., & Bluestone, J. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00662.x · Cited by 1,054
New therapies for treatment of rheumatoid arthritis
Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. H., & Emery, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60784-3 · Cited by 995
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Colombel, J.-F., Panaccione, R., D'Haens, G., Li, J., Rosenfeld, M. R., Kent, J. D., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00159 · Cited by 965
Wells, G., Becker, J.-C., Teng, J., Dougados, M., Schiff, M., Smolen, J., Aletaha, D., & van Riel, P. L. C. M. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.084459 · Cited by 878
Self-citationAdverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
Kremer, J. M., Genant, H. K., Moreland, L. W., Russell, A. S., Emery, P., Abud-Mendoza, C., Szechinski, J., Li, T., Ge, Z., Becker, J.-C., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-12-200606200-00003 · Cited by 715
Self-citationBurmester, G. R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., Gruben, D., Wallenstein, G., Krishnaswami, S., Zwillich, S. H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61424-x · Cited by 714
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642
van Assen, S., Agmon-Levin, N., Elkayam, O., Cervera, R., Doran, M. F., Dougados, M., Emery, P., Geborek, P., Ioannidis, J. P. A., Jayne, D. R. W., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.137216 · Cited by 630
Self-citationAnti-TNF therapy: past, present and future
Monaco, C., Nanchahal, J., Taylor, P., & Feldmann, M. (2015) · International Immunology · doi:10.1093/intimm/dxu102 · Cited by 581
Ruperto, N., Lovell, D. J., Quartier, P., Paz, E., Rubio-Pérez, N., Silva, C. A., Abud-Mendoza, C., Burgos-Vargas, R., Gerloni, V., Melo-Gomes, J. A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60998-8 · Cited by 560
Schiff, M., Keiserman, M., Codding, C., Songcharoen, S., Berman, A., Nayiager, S., Saldate, C., Li, T., Aranda, R., Becker, J.-C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.080002 · Cited by 539
Self-citationCEACAM1: contact-dependent control of immunity
Gray-Owen, S. D., & Blumberg, R. S. (2006) · Nature Reviews Immunology · doi:10.1038/nri1864 · Cited by 537
Smolen, J. S., Kay, J., Doyle, M. K., Landewé, R., Matteson, E. L., Wollenhaupt, J., Gaylis, N., Murphy, F. T., Neal, J. S., Zhou, Y., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60506-7 · Cited by 526
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
Edwards, J. C. W., & Cambridge, G. (2006) · Nature Reviews Immunology · doi:10.1038/nri1838 · Cited by 507
Salliot, C., Dougados, M., & Gossec, L. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083188 · Cited by 477
Self-citationRheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
Smolen, J. S., & Aletaha, D. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.8 · Cited by 474
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
Singh, J. A., Christensen, R., Wells, G. A., Suarez-Almazor, M. E., Buchbinder, R., Lopez-Olivo, M. A., Ghogomu, E. T., & Tugwell, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007848.pub2 · Cited by 470
Genomic landscape of cutaneous T cell lymphoma
Choi, J., Goh, G., Walradt, T., Hong, B. S., Bunick, C. G., Chen, K., Bjornson, R. D., Maman, Y., Wang, T., Tordoff, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3356 · Cited by 428
Juvenile Idiopathic Arthritis: Will Etanercept be an Improvement over Current Therapies?
De Benedetti, F., & Ravelli, A. (2000) · BioDrugs · doi:10.2165/00063030-200014020-00003 · Cited by 428
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?
Engelen, S. E., Robinson, A. J. B., Zurke, Y.-X., & Monaco, C. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00668-4 · Cited by 425
Genovese, M. C., Fleischmann, R., Combe, B., Hall, S., Rubbert-Roth, A., Zhang, Y., Zhou, Y., Mohamed, M.-E. F., Meerwein, S., & Pangan, A. L. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31116-4 · Cited by 422
Self-citationSmolen, J. S., Landewé, R., Breedveld, F. C., Dougados, M., Emery, P., Gaujoux-Viala, C., Gorter, S., Knevel, R., Nam, J., Schoels, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.126532 · Cited by 409
Self-citationNam, J. L., Winthrop, K. L., van Vollenhoven, R. F., Pavelka, K., Valesini, G., Hensor, E. M. A., Worthy, G., Landewé, R., Smolen, J. S., Emery, P., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.126573 · Cited by 406
A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis
Langford, C. A., Cuthbertson, D., Ytterberg, S. R., Khalidi, N., Monach, P. A., Carette, S., Seo, P., Moreland, L. W., Weisman, M., Koening, C. L., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40044 · Cited by 394
Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391
Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis
Taylor, P. C., & Feldmann, M. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.181 · Cited by 389
CD3-specific antibodies: a portal to the treatment of autoimmunity
Chatenoud, L., & Bluestone, J. A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2134 · Cited by 388
Weinblatt, M., Combe, B., Covucci, A., Aranda, R., Becker, J. C., & Keystone, E. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22070 · Cited by 386
Self-citationAbatacept in B7-1–Positive Proteinuric Kidney Disease
Yu, C.-C., Fornoni, A., Weins, A., Hakroush, S., Maiguel, D., Sageshima, J., Chen, L., Ciancio, G., Faridi, M. H., Behr, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304572 · Cited by 384
Merrill, J. T., Burgos‐Vargas, R., Westhovens, R., Chalmers, A., D'Cruz, D., Wallace, D. J., Bae, S. C., Sigal, L., Becker, J. ‐., Kelly, S., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27601 · Cited by 376
Self-citationNoss, E. H., & Brenner, M. B. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00648.x · Cited by 357
Nam, J. L., Ramiro, S., Gaujoux-Viala, C., Takase, K., Leon-Garcia, M., Emery, P., Gossec, L., Landewe, R., Smolen, J. S., & Buch, M. H. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204577 · Cited by 354
MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis
Morand, E. F., Leech, M., & Bernhagen, J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2029 · Cited by 351
Rheumatoid arthritis and cardiovascular disease
Crowson, C. S., Liao, K. P., Davis, J. M., Solomon, D. H., Matteson, E. L., Knutson, K. L., Hlatky, M. A., & Gabriel, S. E. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.07.010 · Cited by 351
Westhovens, R., Robles, M., Ximenes, A. C., Nayiager, S., Wollenhaupt, J., Durez, P., Gomez-Reino, J., Grassi, W., Haraoui, B., Shergy, W., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101121 · Cited by 348
Self-citationDrugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics
Li, P., Zheng, Y., & Chen, X. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00460 · Cited by 346
Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study
Furie, R., Nicholls, K., Cheng, T., Houssiau, F., Burgos‐Vargas, R., Chen, S., Hillson, J. L., Meadows‐Shropshire, S., Kinaszczuk, M., & Merrill, J. T. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38260 · Cited by 341
Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation
Cader, M. Z., & Kaser, A. (2013) · Gut · doi:10.1136/gutjnl-2012-303955 · Cited by 337
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution
Kuek, A., Hazleman, B. L., & Östör, A. J. K. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.052688 · Cited by 335
BYKERK, V. P., AKHAVAN, P., HAZLEWOOD, G. S., SCHIEIR, O., DOOLEY, A., HARAOUI, B., KHRAISHI, M., LECLERCQ, S. A., LÉGARÉ, J., MOSHER, D. P., et al. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.110207 · Cited by 335
Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care
Curtis, J. R., & Singh, J. A. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.05.044 · Cited by 326
Assessing Response and Loss of Response to Biological Therapies in IBD
Yanai, H., & Hanauer, S. B. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.103 · Cited by 326
Therapeutic advances in rheumatoid arthritis
Brown, P., Pratt, A. G., & Hyrich, K. L. (2024) · BMJ · doi:10.1136/bmj-2022-070856 · Cited by 312
Utility of animal models for identification of potential therapeutics for rheumatoid arthritis
Hegen, M., Keith, J. C., Collins, M., & Nickerson-Nutter, C. L. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.076430 · Cited by 305
State-of-the-art: rheumatoid arthritis
McInnes, I. B., & O'Dell, J. R. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.134684 · Cited by 303
Mease, P., Genovese, M. C., Gladstein, G., Kivitz, A. J., Ritchlin, C., Tak, P. P., Wollenhaupt, J., Bahary, O., Becker, J., Kelly, S., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30176 · Cited by 300
Self-citationTrial of Upadacitinib or Abatacept in Rheumatoid Arthritis
Rubbert-Roth, A., Enejosa, J., Pangan, A. L., Haraoui, B., Rischmueller, M., Khan, N., Zhang, Y., Martin, N., & Xavier, R. M. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2008250 · Cited by 298
CTLA-4: From mechanism to autoimmune therapy
Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., & Baradaran, B. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106221 · Cited by 297
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity
Zhang, Q., & Vignali, D. A. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.017 · Cited by 296
Lopez-Olivo, M. A., Tayar, J. H., Martinez-Lopez, J. A., Pollono, E. N., Cueto, J. P., Gonzales-Crespo, M. R., Fulton, S., & Suarez-Almazor, M. E. (2012) · JAMA · doi:10.1001/2012.jama.10857 · Cited by 295
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
Furst, D. E. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.10.002 · Cited by 291
The ACCESS Trial Group (2014) · Arthritis & Rheumatology · doi:10.1002/art.38790 · Cited by 288
An Enigmatic Tail of CD28 Signaling
Boomer, J. S., & Green, J. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002436 · Cited by 283
“…realized with the approval and marketing of a humanized version of CTLA4Ig (abatacept, OrenciaTM) for the treatment of rheumatoid arthritis in adults and Stills disease in children (Genovese et al. 2005) and is being explored for other conditions (Linsley and Nadler 2009; Podojil and Miller 2009).”
BackgroundCampbell, L., Chen, C., Bhagat, S. S., Parker, R. A., & Ostor, A. J. K. (2011) · Rheumatology · doi:10.1093/rheumatology/keq343 · Cited by 282
Treatment of rheumatoid arthritis: state of the art 2009
van Vollenhoven, R. F. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.182 · Cited by 277
Systematic review: colitis associated with anti‐CTLA‐4 therapy
Gupta, A., De Felice, K. M., Loftus, E. V., & Khanna, S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13281 · Cited by 273
Rubbert-Roth, A., & Finckh, A. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2666 · Cited by 266
Genovese, M. C., Schiff, M., Luggen, M., Becker, J.-C., Aranda, R., Teng, J., Li, T., Schmidely, N., Le Bars, M., & Dougados, M. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.074773 · Cited by 264
Self-citationSynovial tissue research: a state-of-the-art review
Orr, C., Vieira-Sousa, E., Boyle, D. L., Buch, M. H., Buckley, C. D., Cañete, J. D., Catrina, A. I., Choy, E. H. S., Emery, P., Fearon, U., et al. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.115 · Cited by 264
Cho, J. H., & Feldman, M. (2015) · Nature Medicine · doi:10.1038/nm.3897 · Cited by 260
Averting inflammation by targeting the cytokine environment
Kopf, M., Bachmann, M. F., & Marsland, B. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2805 · Cited by 257
Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1
Aikawa, Y., Morimoto, K., Yamamoto, T., Chaki, H., Hashiramoto, A., Narita, H., Hirono, S., & Shiozawa, S. (2008) · Nature Biotechnology · doi:10.1038/nbt1412 · Cited by 214
Genovese, M. C., Greenwald, M., Cho, C., Berman, A., Jin, L., Cameron, G. S., Benichou, O., Xie, L., Braun, D., Berclaz, P., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38617 · Cited by 211
Genovese, M. C., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., Valente, R., Nash, P., Simon‐Campos, J. A., Porawska, W., Box, J., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30463 · Cited by 196
Self-citationBlanco, F. J., Möricke, R., Dokoupilova, E., Codding, C., Neal, J., Andersson, M., Rohrer, S., & Richards, H. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40070 · Cited by 185
Fleischmann, R., van Adelsberg, J., Lin, Y., Castelar‐Pinheiro, G. D. R., Brzezicki, J., Hrycaj, P., Graham, N. M. H., van Hoogstraten, H., Bauer, D., & Burmester, G. R. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39944 · Cited by 178
The problem of choice: current biologic agents and future prospects in RA
Choy, E. H., Kavanaugh, A. F., & Jones, S. A. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.8 · Cited by 141
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Russell, W. E., Bundy, B. N., Anderson, M. S., Cooney, L. A., Gitelman, S. E., Goland, R. S., Gottlieb, P. A., Greenbaum, C. J., Haller, M. J., Krischer, J. P., et al. (2023) · Diabetes Care · doi:10.2337/dc22-2200 · Cited by 108
Cremasco, V., Graham, D. B., Novack, D. V., Swat, W., & Faccio, R. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23757 · Cited by 51
Raijmakers, R. P. H., Sprenkeler, E. G. G., Aleva, F. E., Jacobs, C. W. M., Kanneganti, T.-D., Joosten, L. A. B., van de Veerdonk, F. L., & Gresnigt, M. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-11738-4 · Cited by 16
Monoclonal Antibodies: A Prospective and Retrospective View
Sivaccumar, J., Sandomenico, A., Vitagliano, L., & Ruvo, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200219142231 · Cited by 14
Metadata
- Authors
- Genovese, M. C., Becker, J.-C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., Li, T., Aranda, R., Hagerty, D. T., & Dougados, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-09-15
- Volume
- 353
- Issue
- 11
- Pages
- 1114-1123
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2124670599
- Cited by
- 1,241
- References
- 24
- FWCI
- 49.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.